SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending following news of Elon Musk's $1 billion stock purchase, signaling confidence in the company's future and sparking a rally among investors. The community is debating whether this is a long-term bullish signal or a short-term pump, with some focusing on the company's potential in robotics and AI, while others point to ongoing concerns about valuation and market competition.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as retail traders speculate on potential government contracts following a congressional disclosure of stock purchases, sparking comparisons to $PLTR. The community is actively discussing chart patterns and a potential short squeeze, with bullish investors highlighting the company's AI-driven solutions and anticipating a breakout. Chatter revolves around potential gains amidst growing interest in AI for defense and security.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU.X is trending as its community rallies around its real-world brand-building efforts and growing holder base, highlighting a new energy drink flavor and upcoming meet-up. Community members express strong conviction in the project's long-term potential, emphasizing its unique approach and active development. Despite market fluctuations, the community remains focused on organic growth and strategic initiatives.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle ($ORCL) is trending amid speculation around its involvement in a potential TikTok deal, with community members discussing the likelihood and potential impact of such an acquisition. Some traders believe positive news could send the stock soaring, while others express skepticism about the deal's value and sustainability, pointing to concerns about a possible "pump and dump" scenario. The stock's recent volatility, following a significant post-earnings surge, is also fueling debate about its near-term direction.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Inu is trending as its community, the Wolfpack, rallies around the project, drawing comparisons to the early days of Shiba Inu and Saitama. Community members express strong conviction, anticipating significant gains and highlighting the project's solid floor and dedicated development team. Talk centers around a potential breakout and the revival of the 'Inu season' within the crypto space.

Slopana

$SLOPANA.X is gaining traction as the self-proclaimed 'king of digital slop,' capitalizing on the meme coin frenzy within the Solana ecosystem. Community members highlight its strong community, CTO leadership and are actively encouraging others to join before a potential surge, referencing its availability on Phantom Wallet.

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics is trending after announcing a $5.7 billion deal with Novartis, sparking significant gains. The community is discussing the potential for further upside, upgrades, and a possible short squeeze given the positive news. Some traders are taking profits, while others remain bullish, anticipating a multi-day run.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire ($RDW) is trending amid a newly announced partnership with Honeywell to develop quantum-secure satellite communication systems. The community is focused on the potential of this collaboration, particularly its implications for the company's future earnings and potential for a short squeeze given high short interest. Some investors are also weighing in on a recent settlement related to accounting irregularities, while others express optimism about the space sector and RDW's long-term prospects.

The New York Times Co. is a media organization, which engages in creating, collecting, and distributing news and information. It offers news products and other interest-specific products, and related content and services. It offers newspapers, print, and digital products and investments. The firm also manages The New York Times, NYTimes.com, and mobile applications. The company was founded by Henry Jarvis Raymond and George Jones on September 18, 1851, and is headquartered in New York, NY.

New York Times Co. - Ordinary Shares - Class A

New York Times ($NYT) is trending due to Trump's recent announcement of a $15 billion defamation lawsuit against the publication, sparking community debate about potential impacts. Earnings and AI deals have also captured attention, with community members weighing the potential for growth through digital subscriptions and partnerships with companies like Amazon. Some traders are discussing ratings and price targets from analysts, as well as potential market plays.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as investors anticipate a potential rate cut decision from the Federal Reserve, while some traders express concerns about overvaluation and a possible "sell the news" event. Community chatter revolves around the sustainability of the current rally, with discussions about market mechanics, potential pullbacks, and the impact of the Fed's actions, as well as signs that insiders are selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Chimerix Inc. (CMRX) more than tripled on Tuesday afternoon, reaching levels unseen in over two years, becoming one of the top 25 most active tickers on Stocktwits.&nbsp;The microcap biopharmaceutical company announced plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Dordaviprone under the Accelerated Approval pathway by the end of the year.&nbsp;Dordaviprone is being developed as a treatment for certain patients with diffuse glioma, a rare and aggressive type of brain cancer.Chimerix noted that Dordaviprone has received Rare Pediatric Disease Designation for H3 K27M-mutant glioma and said it intends to apply for a Rare Pediatric Disease Priority Review Voucher along with its NDA submission.CEO Mike Andriole emphasized the potential impact of the drug, stating: “If approved, dordaviprone will fundamentally change the treatment landscape for patients suffering from this lethal form of brain cancer who have extremely limited treatment options.”&nbsp;“We have worked collaboratively with the U.S. FDA, disease experts and patient advocates throughout the year to potentially accelerate access to dordaviprone for this patient community,” he added.The company also announced preparations for a potential U.S. launch by the third quarter of 2025, contingent on application acceptance and Priority Review.Following the news, JonesResearch raised its price target on Chimerix to $7 from $5 while maintaining a ‘Buy’ rating.&nbsp;Analysts highlighted the company’s strategic focus on the U.S. NDA submission while halting Australian approval efforts.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CMRX_sentiment_and_message_volume_Dec_10_premarket_4d3fa2af57.png" alt="CMRX sentiment and message volume Dec 10 premarket.png" width="1318" height="324"><figcaption>CMRX sentiment and message volume Dec 10 as of 1:15 pm ET | source: Stocktwits</figcaption></figure>Retail sentiment for CMRX turned 'extremely bullish', with users on Stocktwits highlighting the stock’s potential for further gains.<stembedurl>https://stocktwits.com/jengtap/message/595886939</stembedurl><stembedurl>https://stocktwits.com/investvibes/message/595887869</stembedurl>Chimerix shares, whose message volume has spiked over 2,540% in the past week, have surged nearly 200% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medicine pill is seen in a hand dressed in a medical glove with the U.S. FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) 

Chimerix Stock Draws Heavy Retail Chatter After Landing Price-Target Hike On FDA Submission Plan For Cancer Drug 

Following the news, JonesResearch raised its price target on Chimerix to $7 from $5 while maintaining a ‘Buy’ rating.

Equity

Shares of GeoVax Labs Inc. (<a class="mention" data-mention="$GOVX" data-symbol-id="GOVX" href="https://stocktwits.com/symbol/GOVX" target="_blank">$GOVX</a>), SIGA Technologies Inc. (<a class="mention" data-mention="$SIGA" data-symbol-id="SIGA" href="https://stocktwits.com/symbol/SIGA" target="_blank">$SIGA</a>), and Emergent Biosolutions Inc. (<a class="mention" data-mention="$EBS" data-symbol-id="EBS" href="https://stocktwits.com/symbol/EBS" target="_blank">$EBS</a>) gained in mid-day trading on Friday after the World Health Organisation (WHO) reaffirmed that the ongoing upsurge of mpox remains a public health emergency of international concern (PHEIC).Mpox, formerly called monkeypox, is a disease similar to smallpox caused by a virus.&nbsp;“The decision was based on the rising number and continuing geographic spread of cases, operational challenges in the field, and the need to mount and sustain a cohesive response across countries and partners,” the apex health agency said in a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/WHO/status/1860015125463175343">post</a> on X (formerly Twitter).&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_132250_27d9a22ffc.png" alt="Screenshot 2024-11-22 132250.png">The WHO first declared mpox a PHEIC in August earlier this year because a new strain of the virus, Clade Ib, had spread to countries that had not previously reported any incidences of the disease, like Thailand and Sweden.&nbsp;Shares of GeoVax, currently working on a vaccine for mpox and smallpox, were up nearly 10% in mid-day trading on Friday. The stock has lost 47% of its value this year so far.&nbsp;<stembedurl>https://stocktwits.com/gabbs/message/593724551</stembedurl>Meanwhile, shares of SIGA Technologies Inc. (<a class="mention" data-mention="$SIGA" data-symbol-id="SIGA" href="https://stocktwits.com/symbol/SIGA" target="_blank">$SIGA</a>), developing an investigational drug for treating mpox called tecovirimat (TPOXX),&nbsp; jumped 2.5% after the news.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_134247_8c8f14c041.png" alt="Screenshot 2024-11-22 134247.png">Retail sentiment around the stock improved to ‘bullish’ (60/100) from ‘neutral’ a day ago.&nbsp;SIGA Technologies’ shares have gained 11% this year so far.There was less movement around Emergent Biosolutions Inc. (<a class="mention" data-mention="$EBS" data-symbol-id="EBS" href="https://stocktwits.com/symbol/EBS" target="_blank">$EBS</a>), also working on a vaccine for mpox, which saw a marginal uptick of 0.6% in mid-day trading on Friday.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_134547_d67811671e.png" alt="Screenshot 2024-11-22 134547.png">Retail sentiment around the stock remained in the ‘neutral’ zone with no significant change in chatter.&nbsp;Emergent Biosolutions’ vaccine, approved for smallpox, has also been used as a mpox shot, but the U.S. Food and Drug Administration is yet to approve its application for use against the virus.<stembedurl>https://stocktwits.com/WinstonSmith33/message/593679534</stembedurl>In 2022, the company acquired the rights to a smallpox treatment called Tembexa, which was developed by Chimerix Inc. ($CMRX), for up to $337.5 million plus royalties.Chimerix was up around 0.6% as well during mid-day trading.&nbsp;For updates and corrections email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/agrify-stock-doubles-to-hit-over-1-year-high-after-25-9-m-placement-but-retail-wary-of-short-covering-rally/cJIdTKHRg3">Agrify Stock Doubles To Hit Over 1-Year High After $25.9M Placement, But Retail Wary Of Short-Covering Rally</a>

Mpox, formerly called monkeypox, is a disease similar to smallpox caused by a virus. | Source: Pexels

GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks

Emergent Biosolutions and Chimerix also saw marginal gains after the announcement. 

<h1>These Three Stocks are Experiencing an Outbreak– Or a Breakout Depending How you Look at it</h1><h3>Monkeypox Outbreak Fuels Surge in Related Biopharma Stocks</h3>The recent resurgence of monkeypox has sparked widespread concern and reignited the market's interest in companies working to combat viral diseases. As the outbreak spreads, parallels to the COVID-19 pandemic are being drawn in both the media and financial markets. During the COVID-19 crisis, pharmaceutical companies that developed vaccines, treatments, and diagnostics experienced unprecedented growth, with investors flocking to these stocks in search of gains. Now, as the world faces another potential health emergency, a new set of companies is stepping into the spotlight.The global health community and investors alike are keeping a close eye on monkeypox, a disease caused by the monkeypox virus, which shares similarities with smallpox. While the outbreaks have been sporadic and relatively contained in the past, recent concerns have shifted focus toward vaccine and treatment development. The monkeypox market, although smaller in scope than COVID-19, holds significant potential. The World Health Organization and public health bodies are calling for increased awareness, testing, and vaccination. As a result, companies developing monkeypox-related therapies and vaccines are seeing their stock prices soar.Three such companies—GeoVax Labs, Tonix Pharmaceuticals, and Chimerix—are garnering substantial interest. All three have ties to the smallpox market, which, in turn, gives them relevance in the monkeypox conversation. Below is a review of these companies, their roles in combating the outbreak, and their stock performance over the short, medium, and long term.<a href="https://wealthyvc.com/featured/tiny-healthcare-stock-with-35-million-market-cap-becomes-major-player-overnight-in-rapidly-growing-1-billion-market/">This Tiny Healthcare Stock With $35M Market Cap Becomes Major Player Overnight in Rapidly Growing $1 Billion Blood Clot Market</a><a href="https://stocktwits.com/symbol/GOVX">GeoVax Labs (NASDAQ: GOVX)</a>GeoVax Labs has emerged as one of the frontrunners in the monkeypox vaccine race. Based in Georgia, this clinical-stage biotechnology company specializes in vaccines that leverage its proprietary Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) platform. The company has been developing vaccines for various infectious diseases, including smallpox, Ebola, and Lassa fever. However, with the recent monkeypox outbreak, GeoVax's focus on viral hemorrhagic fevers and poxvirus diseases has become particularly relevant.GeoVax's stock soared as concerns around monkeypox escalated, with investors seeing potential in its MVA-based vaccine technology. Its smallpox vaccine is designed to offer cross-protection against monkeypox due to the close relation between the two viruses. This has made GeoVax a significant player in the biopharma space, as public health agencies explore all options for controlling the spread of the virus.<ul><li>1-Day Return: +33%</li><li>1-Month Return: +234%</li><li>1-Year Return: +21%</li></ul>GeoVax shares have experienced strong upward momentum over the past month, driven by mounting concerns over monkeypox. Over the past year, the stock has gained substantial value as the company has positioned itself as a leader in the viral vaccine space.<a href="https://stocktwits.com/symbol/TNXP">Tonix Pharmaceuticals (NASDAQ: TNXP)</a><a href="https://stocktwits.com/symbol/TNXP"><img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_19_at_9_53_43_PM_2ed6d91698.png" alt="Screenshot 2024-08-19 at 9.53.43 PM.png"></a>Tonix Pharmaceuticals, another biotech firm in the spotlight, is developing live virus vaccines that may offer protection against monkeypox and other orthopoxvirus diseases. Based in New Jersey, Tonix has focused on immunology, chronic diseases, and rare infectious diseases. One of its notable projects is its live virus vaccine candidate, TNX-801, designed to protect against both smallpox and monkeypox.A recent Benzinga article highlighted the company’s preclinical results, which demonstrated long-term immunity and protection against these viruses. Tonix’s TNX-801 is based on a horsepox viral platform, which is closely related to smallpox and monkeypox. The company is working on creating a robust, durable immune response that can withstand mutations and future outbreaks. What makes Tonix attractive is the potential for TNX-801 to be used as a preventive measure in populations at high risk of contracting monkeypox.<ul><li>1-Day Return: +40%</li><li>1-Month Return: +12%</li><li>1-Year Return: -98%</li></ul>Tonix Pharmaceuticals has seen a notable rise in its stock price over the past month, as interest in its vaccine candidate has intensified. However, the stock’s performance over the past year reflects the inherent volatility in biotech investing, with a significant drop amid broader market conditions and uncertainty in the clinical trial space.<a href="https://stocktwits.com/symbol/CMRX">Chimerix, Inc. (NASDAQ: CMRX)</a><a href="https://stocktwits.com/symbol/CMRX"><img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_19_at_9_54_50_PM_c72f46e0e8.png" alt="Screenshot 2024-08-19 at 9.54.50 PM.png"></a>Chimerix, Inc., a biotechnology company based in North Carolina, is another name linked to the monkeypox outbreak. While the company gained attention for its smallpox drug, Tembexa, the renewed interest in orthopoxviruses like monkeypox has brought Chimerix back into the conversation. Tembexa (brincidofovir) is an FDA-approved treatment for smallpox, which gives Chimerix an edge as governments explore stockpiling options for poxvirus diseases.Though Chimerix has not explicitly developed a monkeypox treatment, the parallels between smallpox and monkeypox suggest that Tembexa could play a role in mitigating the effects of the outbreak. The drug's broad-spectrum antiviral activity makes it a candidate for off-label use in monkeypox cases. In a market where few treatments exist, Chimerix’s existing FDA approval for Tembexa may provide a quicker pathway for emergency use if the monkeypox crisis intensifies.<ul><li>1-Day Return: +5%</li><li>1-Month Return: +20%</li><li>1-Year Return: +14%</li></ul>Chimerix’s stock has seen a short-term bump as investors reevaluate its smallpox drug in light of the monkeypox outbreak. However, much like Tonix, the stock’s performance over the past year has been challenging, marked by sell-offs and investor uncertainty around the company’s long-term prospects.ConclusionAs monkeypox continues to spread, the market is once again turning to biopharmaceutical companies for solutions.&nbsp;GeoVax Labs,&nbsp;Tonix Pharmaceuticals, and&nbsp;Chimerix Inc. are at the forefront of efforts to address this public health crisis, each leveraging its expertise in smallpox and viral disease research. While the global market for monkeypox treatments is still emerging, these companies are well-positioned to capture the growing demand for vaccines and antiviral treatments.Investors should keep a close eye on clinical developments, regulatory approvals, and government stockpiling programs, as these will be key drivers of stock performance in the coming months. Like the COVID-19 pandemic, the monkeypox outbreak has the potential to create significant winners in the biotech sector. However, as always with biopharma stocks, the risks are high, and careful due diligence is necessary before jumping into this volatile space.&nbsp;Read Next:&nbsp;<a href="https://wealthyvc.com/featured/tiny-healthcare-stock-with-35-million-market-cap-becomes-major-player-overnight-in-rapidly-growing-1-billion-market/">This Tiny Healthcare Stock With $35M Market Cap Becomes Major Player Overnight in Rapidly Growing $1 Billion Blood Clot Market</a><a href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at&nbsp;<a href="mailto:Invest@WealthyVC.com">Invest@WealthyVC.com</a>This article is from an unpaid external contributor. It does not represent Stocktwits reporting or views and has not been edited for content or accuracy.&nbsp;&nbsp;

These Three Stocks are Experiencing an Outbreak– Or a Breakout Depending How you Look at it

GeoVax Labs, Tonix Pharmaceuticals, and Chimerix see stock surge amid monkeypox outbreak, leveraging their expertise in viral diseases and smallpox-related vaccines.

Monkeypox Outbreak Boosts These Biopharma Stocks

The monkeypox outbreak has boosted stocks of GeoVax Labs, Tonix Pharmaceuticals, and Chimerix. These companies are developing vaccines and treatments related to smallpox and viral diseases, positioning them as key players in addressing this health crisis.

Chimerix Board Changes: Machado Resigns, Kozin Appointed

The latest announcement is out from Chimerix (CMRX). Patrick Machado has announced his resignation from the Board of Directors of Chimerix, Inc., e...

Chimerix Appoints Marc D. Kozin to Board of Directors

Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy ExperienceDURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose...

Chimerix (NASDAQ:CMRX) Raised to "Hold" at StockNews.com

StockNews.com upgraded shares of Chimerix (NASDAQ:CMRX  Free Report) from a sell rating to a hold rating in a research report released on Monday.
Other research analysts also recently issued...

Chimerix Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Chimerix ( NASDAQ:CMRX ) Full Year 2023 Results Key Financial Results Net loss: US$82.1m (down by 148% from US$172.2m...

Chimerix: Tackling A Strong Unmet Need With Promising Data

Chimerix: Tackling A Strong Unmet Need With Promising Data...

Chimerix files $250M mixed securities shelf

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 Phase 2 ONC201 Data Published in Peer-Reviewed Journal of Clinical Oncology $204...

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.

Chimerix Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

Current Price	$8.55
Prev Close	$8.55
Open	$8.55
Dividend Yield	0.00%
50-Day Moving Average	$7.86
Beta	1.10
Avg. Volume	1.36M
PE Ratio	-8.67

52-Week High	$8.55
52-Week Low	$0.75
Market Capitalization	$801.08M
EPS (Annual)	-$0.9854
Price to Book	6.47
Revenue Per Employee	$2,617.28
Enterprise Value/EBITDA	N/A

CMRX
Chimerix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CMRX News

CMRX Chimerix Inc